Armata Pharmaceuticals (ARMP) has significantly outperformed the Medical sector year-to-date, achieving a 68.7% return against the sector's 3.6% average, driven by a 24.7% increase in its full-year earnings estimate over the past three months and a Zacks Rank #2 (Buy). This strong performance, also seen in Halozyme Therapeutics (HALO) with a 44.3% YTD gain and a Zacks Rank #1 (Strong Buy), highlights specific medical stocks with improving earnings outlooks and robust investor sentiment, warranting continued tracking by investors.
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. If you wish to go to ZacksTrade, click OK. If you do not, click Cancel. Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year? Read MoreHide Full Article For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Armata Pharmaceuticals, Inc. (ARMP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Armata Pharmaceuticals, Inc. is a member of the Medical sector. This group includes 960 individual stocks and currently holds a Zacks Sector Rank of 5. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Armata Pharmaceuticals, Inc. is currently sporting a Zacks Rank of 2 (Buy). Over the past three months, the Zacks Consensus Estimate for ARMP's full-year earnings has moved 24.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving. According to our latest data, ARMP has moved about 68.7% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 3.6% on a year-to-date basis. This shows that Armata Pharmaceuticals, Inc. is outperforming its peers so far this year. One other Medical stock that has outperformed the sector so far this year is Halozyme Therapeutics (HALO - Free Report) . The stock is up 44.3% year-to-date. Over the past three months, Halozyme Therapeutics' consensus EPS estimate for the current year has increased 14.1%. The stock currently has a Zacks Rank 1 (Strong Buy). Looking more specifically, Armata Pharmaceuticals, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 472 individual stocks and currently sits at 79 in the Zacks Industry Rank. Stocks in this group have gained about 9.8% so far this year, so ARMP is performing better this group in terms of year-to-date returns. Halozyme Therapeutics is also part of the same industry. Investors with an interest in Medical stocks should continue to track Armata Pharmaceuticals, Inc. and Halozyme Therapeutics. These stocks will be looking to continue their solid performance. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Image: Bigstock Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year? For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Armata Pharmaceuticals, Inc. (ARMP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Armata Pharmaceuticals, Inc. is a member of the Medical sector. This group includes 960 individual stocks and currently holds a Zacks Sector Rank of 5. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Armata Pharmaceuticals, Inc. is currently sporting a Zacks Rank of 2 (Buy). Over the past three months, the Zacks Consensus Estimate for ARMP's full-year earnings has moved 24.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving. According to our latest data, ARMP has moved about 68.7% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 3.6% on a year-to-date basis. This shows that Armata Pharmaceuticals, Inc. is outperforming its peers so far this year. One other Medical stock that has outperformed the sector so far this year is Halozyme Therapeutics (HALO - Free Report) . The stock is up 44.3% year-to-date. Over the past three months, Halozyme Therapeutics' consensus EPS estimate for the current year has increased 14.1%. The stock currently has a Zacks Rank 1 (Strong Buy). Looking more specifically, Armata Pharmaceuticals, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 472 individual stocks and currently sits at 79 in the Zacks Industry Rank. Stocks in this group have gained about 9.8% so far this year, so ARMP is performing better this group in terms of year-to-date returns. Halozyme Therapeutics is also part of the same industry. Investors with an interest in Medical stocks should continue to track Armata Pharmaceuticals, Inc. and Halozyme Therapeutics. These stocks will be looking to continue their solid performance. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Armata Pharmaceuticals (ARMP) is demonstrating significant market outperformance, with its stock appreciating 68.7% year-to-date, starkly contrasting with the broader Medical sector's average return of 3.6% and its direct industry group's gain of 9.8%. The primary catalyst for this momentum appears to be a marked improvement in its earnings outlook, evidenced by a 24.7% upward revision in the Zacks Consensus Estimate for full-year earnings over the past three months. This has resulted in a Zacks Rank of 2 (Buy), indicating strong positive analyst sentiment. This trend of specific stocks bucking sector weakness is further corroborated by peer Halozyme Therapeutics (HALO), which has gained 44.3% YTD and holds a Zacks Rank 1 (Strong Buy) following a 14.1% increase in its own consensus EPS estimate. The analysis suggests that within a generally lagging Medical sector (Zacks Sector Rank 5), select companies with strong, upwardly revised earnings forecasts are being singled out and rewarded by investors.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
